Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-24T02:04:32.473Z Has data issue: false hasContentIssue false
  • English
  • Français

Proteinuria and clinical outcome in CHD patients

Published online by Cambridge University Press:  28 August 2014

Efrén Martínez-Quintana  and
Fayna Rodríguez-González
Efrén Martínez-Quintana*
Affiliation:
Cardiology Service, Insular-Materno Infantil University HospitalLas Palmas de Gran Canaria, Spain
Fayna Rodríguez-González
Affiliation:
Dr. Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain
*
Correspondence to: E. Martínez-Quintana, MD, PhD, Servicio de Cardiología, Complejo Universitario Insular-Materno Infantil, Avenida Marítima del Sur s/n, 35016 Las Palmas de Gran Canaria, Spain. Tel: +00 34 928441360; Fax: +00 34 928441853; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction: CHD patients, especially those with associated hypoxaemia, usually have some level of renal function impairment, even though they are relatively young. The aim of the study was to evaluate those clinical and analytical factors that may contribute to microalbuminuria and determine the association of 24-hour proteinuria with thrombotic events and mortality. Methods: A total of 251 CHD patients were studied and demographic characteristics, blood test, and 24-hour urinalysis were analysed. Results: Of the patients, 221 were non-hypoxaemic, and 30 were hypoxaemic (oxygen saturation of 84.3±5.9%). Of the non-hypoxaemic patients, 30 (13.6%), and of the hypoxaemic patients 9 (30%), showed proteinuria (>0.15 g/24 hours) (p=0.028). Hypoxaemic CHD patients also showed higher haematocrit (%) (50.7 (34.6; 72.1) versus 42.8 (34.6; 48.9), p<0.001), serum creatinine (mg/dl) (1.07±0.2 versus 0.96±1.9, p=0.004), microalbuminuria (mg/dl/24 hours) (1.2 (0.0; 261.5) versus 0.5 (0.0; 4.37), p<0.001), proteinuria (gr/24 hours) (1.0 (0.4; 3.1) versus 0.08 (0.04; 0.52), p=0.043), and N-terminal pro–B-type natriuretic peptide (pg/ml) (417.8 (35.7; 8534.0) versus 44.9 (0.0; 670.5), p<0.001) concentrations than non-hypoxaemic CHD patients. During a median follow-up of 26.0 (16.9; 57.7) months, five patients died – one patient had 24-hour proteinuria and four patients did not (p=0.581) – and three patients had some type of thrombosis – two patients had 24-hour proteinuria and one patient did not (p=0.014). Kaplan–Meier survival analysis showed no significant difference between CHD patients with and without 24-hour proteinuria (p=0.631). Conclusion: CHD patients with proteinuria have significantly more thrombosis and more hypoxaemia than those patients without proteinuria.

Keywords

Congenitalhypoxaemiamicroalbuminuriaproteinuriathrombosisdeath
Type
Original Articles
Information
Cardiology in the Young , Volume 25 , Issue 6 , August 2015 , pp. 1054 - 1059
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Agras, PI, Derbent, M, Ozcay, F, et al. Effect of congenital heart disease on renal function in childhood. Nephron Physiol 2005; 99: 10–15.CrossRefGoogle ScholarPubMed
2. Inatomi, J, Matsuoka, K, Fujimaru, R, Nakagawa, A, Iijima, K. Mechanisms of development and progression of cyanotic nephropathy. Pediatr Nephrol 2006; 21: 1440–1445.Google Scholar
3. Martínez-Quintana, E, Rodríguez-González, F, Fábregas-Brouard, M, Nieto-Lago, V. Serum and 24-hour urine analysis in adult cyanotic and noncyanotic congenital heart disease patients. Congenit Heart Dis 2009; 4: 147–152.CrossRefGoogle ScholarPubMed
4. Kovesdy, CP, Lott, EH, Lu, JL, et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol 2013; 61: 1626–1633.CrossRefGoogle ScholarPubMed
5. Zamora, CR, Cubeddu, LX. Microalbuminuria: do we need a new threshold? J Hum Hypertens 2009; 23: 146–149.CrossRefGoogle Scholar
6. Levey, AS, Greene, T, Kusek, JW, Beck, GJ and MDRD Study Group. A simplified equation to predict GFR from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11 (Suppl): A08028.Google Scholar
7. Stevens, LA, Coresh, J, Greene, T, Levey, AS. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–2483.Google Scholar
8. Quiñones, MA, Otto, CM, Stoddard, M, Waggoner, A, Zoghbi, WA, Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167–184.CrossRefGoogle ScholarPubMed
9. Jones, CA, Francis, ME, Eberhardt, MS, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445–459.CrossRefGoogle ScholarPubMed
10. Dittrich, S, Haas, NA, Bührer, C, Müller, C, Dähnert, I, Lange, PE. Renal impairment in patients with long-standing cyanotic congenital heart disease. Acta Paediatr 1998; 87: 949–954.Google Scholar
11. Yan, SF, Ogawa, S, Stern, DM, Pinsky, DJ. Hypoxia-induced modulation of endothelial cell properties: regulation of barrier function and expression of interleukin-6. Kidney Int 1997; 51: 419–425.CrossRefGoogle ScholarPubMed
12. Perloff, JK. Systemic complications of cyanosis in adults with congenital heart disease – hematologic derangements, renal function, and urate metabolism. Cardiol Clin 1993; 4: 689–699.CrossRefGoogle Scholar
13. Burlet, A, Drukker, A, Guignard, JP. Renal function in cyanotic congenital heart disease. Nephron 1999; 81: 296–300.CrossRefGoogle ScholarPubMed
14. Akita, H, Matsuoka, S, Kuroda, Y. Nephropathy in patients with cyanotic congenital heart disease. Tokushima J Exp Med 1993; 40: 47–53.Google ScholarPubMed
15. Perloff, JK, Latta, H, Barsotti, P. Pathogenesis of the glomerular abnormality in cyanotic congenital heart disease. Am J Cardiol 2000; 86: 1198–1204.CrossRefGoogle ScholarPubMed
16. Gupte, PA, Vaideeswar, P, Kandalkar, BM. Cyanotic nephropathy – a morphometric analysis. Congenit Heart Dis 2014; 9: 280–285.CrossRefGoogle Scholar
17. Elsayed, EF, Tighiouart, H, Griffith, J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130–1136.Google Scholar
18. Hsu, RK, Hsu, CY. Proteinuria and reduced glomerular filtration rate as risk factors for acute kidney injury. Curr Opin Nephrol Hypertens 2011; 20: 211–217.CrossRefGoogle ScholarPubMed
19. Schrier, RW, Abraham, WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577–585.CrossRefGoogle ScholarPubMed
20. Brenner, BM, Lawler, EV, Mackenzie, HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774–1777.CrossRefGoogle ScholarPubMed
21. Faustinella, F, Uzoh, C, Sheikh-Hamad, D, Truong, LD, Olivero, JJ. Glomerulomegaly and proteinuria in a patient with idiopathic pulmonary hypertension. J Am Soc Nephrol 1997; 8: 1966–1970.CrossRefGoogle Scholar
22. Ghafari, S, Malaki, M. Truncus arteriosus: a major cause of proteinuria in children. J Cardiovasc Dis Res 2011; 2: 237–240.CrossRefGoogle Scholar
23. Martínez-Quintana, E, Rodríguez-González, F, Medina-Gil, JM, Agredo-Muñoz, J, Nieto-Lago, V. Clinical outcome in Down syndrome patients with congenital heart disease. Cir Cir 2010; 78: 245–250.Google ScholarPubMed
24. Guzmán, R, Campos, C, López-Fernández, E, Casado, A. Biomarkers of age effect on renal function in Down syndrome. Biomarkers 2011; 16: 679–685.Google Scholar
25. Gerstein, HC, Mann, JF, Yi, Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421–426.CrossRefGoogle ScholarPubMed
26. Tonelli, M, Klarenbach, SW, Lloyd, AM, et al. Higher estimated glomerular filtration rates may be associated with increased risk of adverse outcomes, especially with concomitant proteinuria. Kidney Int 2011; 80: 1306–1314.CrossRefGoogle ScholarPubMed
27. Hemmelgarn, BR, Manns, BJ, Lloyd, A, et al. Relation between kidney function, proteinuria, and adverse outcomes. J Am Med Assoc 2010; 303: 423–429.CrossRefGoogle ScholarPubMed
28. Hillege, HL, Fidler, V, Diercks, GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782.Google Scholar
29. Singh, A, Satchell, SC. Microalbuminuria: causes and implications. Pediatr Nephrol 2011; 26: 1957–1965.Google Scholar